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of thirty four major, not-for-profit agricultural research and education 
institutions in the United States and Canada, is pleased to release the 
enclosed document entitled Recommendations for Management Practices 
for Field Trials with Bioengineered Plants. The document was prepared 
by a subcommittee of our organization after extensive consultation with 
relevant federal agencies. It is intended to guide NABC member 
institutions as they seek to comply with federal regulations related to 
research with experimental bioengineered plants under field conditions. 
But we hope it will be useful, too, to other institutions as they seek to 
conduct such experiments.
Please note that the document provides recommendations only, which are 
subject to the limitations expressed in the document. NABC understands 
that it is the responsibility of the individual institutions to ensure that 
their own particular management practices adhere to federal 
requirements. But we also understand that there are broad, general 
recommendations that are applicable to all institutions conducting such 
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Recommendations for Management Practices 
for Field Trials with Bioengineered Plants
Objective: To assist principal investigators, institutionalbiosafety committees, biosafety officers, field-research site 
managers, administrators and others at NABC-member institutions 
to coordinate their responsibilities in order to comply with federal 
regulations related to the confinement/ containment1 of experimental 
bioengineered plants under field-research conditions.
This document provides only recommendations for the benefit 
of NABC member institutions seeking to comply with federal 
regulations in this area. Each institution is responsible for 
adhering to applicable legal requirements, whether dictated 
by federal, state and/or other laws and regulations. NABC, its 
officers, directors, employees and representatives, assume no 
legal duty or responsibility for any management practices adopted 
by member institutions, without regard to whether such practices 
may be consistent or inconsistent with these recommendations. 
Each institution may use/adopt these recommendations to 
fit its own infrastructure and each institution will have total 
responsibility for its own field tests and any attendant liability. 
If any inconsistencies exist between these recommendations and 
current/future governmental regulations, the latter shall apply. 
NABC expressly disclaims any liability or legal responsibility 
in connection with management practices adopted by member 
institutions.
These recommendations are not intended, and shall not be relied 
upon, to constitute legal advice provided by NABC to member 
institutions. NABC member institutions are encouraged to seek 
legal advice as they, in their judgment, may consider necessary 
and appropriate.
'USDA-APHIS uses the term “confinement,” whereas EPA uses “containment”; “con­
finement” is used elsewhere herein.
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Introduction
These recommendations for management practices (RMPs) provide a framework for admini strators and scientists at NABC-member 
institutions involved in small-scale field-research studies (generally 
<10 acres) on bioengineered2 plants. The RMPs are designed to 
help those involved in public-sector research to comply with federal 
and other regulations with respect to field trials on bioengineered 
plants. The recommendations may be useful also to non-NABC 
land-grant institutions, but that needs to be an individual decision 
since they have had no opportunity to review the contents3; as with 
NABC institutions, they have the responsibility to comply with any 
federal and other regulations. Certain regulatory agencies (USDA- 
APHIS-BRS, EPA, and FDA) have reviewed preliminary drafts, 
but the contents of this document and its recommendations are 
solely NABC’s. Federal regulatory agencies should be contacted 
for clarification of legal requirements. Specific state and local 
requirements are not addressed. The recommendations apply only 
to the United States4.
The document is intended to be broadly relevant to the testing of 
plant and tree crops used in agriculture, horticulture, and forestry 
(i.e. grain and cereal crops, grain and forage legumes, grasses, 
fruits, vegetables, tree fruits, tobacco, fiber crops, ornamentals, 
forestry trees, etc.). To date, the experience base is broadest with 
corn, soybean, cotton, and canola, therefore it is written with these 
field crops specifically in mind, although field tests have been 
made under the aegis of USDA-APHIS-Biotechnology Regulatory 
Services (-BRS) with several other species.
2Bioengineered” is used in this document as it is by USDA-APH3S-BRS; alternative terms 
include “transgenic,” “genetically engineered” and “genetically modified.”
3NABC council members reviewed these RMPs and provided comments that were con­
sidered and incorporated.
4The document does not cover the aspects of APHIS regulations related to movement 
from one contained facility (such as a laboratory) to another if the movement is into 
the United States or from one state to another state or territory of the US. Such consid­
erations may be relevant to researchers receiving regulated articles from colleagues in 
other institutions. The shipment of bioengineered organisms from the United States to 
other countries will be subject to the relevant regulations of the receiving country or cer­
tain international treaties and protocols, such as the Cartagena Protocol for Biosafety.
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These recommendations may be modified in the future to reflect 
changes in federal regulations—presumably using this document 
as the starting material—and additions may be made in due 
course to encompass more crops as the experience base expands. 
Although NABC intends to use its best efforts to communicate 
such changes to member institutions and to do so on a timely basis, 
NABC assumes no legal duty or responsibility in this regard. These 
recommendations do not apply to bioengineered plants already 
approved for commercial use.
Institutional Biosafety Committees (IBCs) have played a major 
role in achieving successful oversight of laboratory and greenhouse 
experimentation for over 20 years, and have been active also in field 
testing at many institutions. Under these RMPs, it is recommended 
that each institution utilize its IBC to play an equivalent role 
in overseeing field experimentation with bioengineered plants. 
It is recommended that the IBC have at least one member with 
experience in field experimentation, preferably with bioengineered 
crops. A subcommittee—composed largely of individuals with 
relevant experience in field research and bioengineered plants—may 
have an advisory role; in this document it is termed the IBC-Field 
Subcommittee (“IBC-F”). If an IBC-F is advantageous—e.g. at 
institutions where large numbers of bioengineered crops are under 
experimentation—at least the chairperson of the IBC-F should be a 
member of the IBC.
Each institution should establish in writing the relative roles 
of the principle investigator (PI), the IBC, the biosafety officer, 
field manager(s) and senior research administration to ensure that 
requirements are met for approvals from federal (see Appendix) 
state and local authorities, and identify the single overall responsible 
party.
The Recommendations
Application, institutional responsibility, approvals, training, field- site selection, record-keeping, communications, storage and 
disposal of biological materials, appropriate treatment of equipment
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including cleaning, monitoring, testing, and reporting are processes 
common to all research on experimental bioengineered plants.
Application
The application(s) for approval to conduct a field test should be 
prepared by the PI for approval by the IBC and by federal and, if 
required, state and local agencies. The application must include 
information required by the regulatory agency, e.g. the transgene(s), 
protein(s) produced, the parent plant and relevant information from 
laboratory and greenhouse tests. Confinement protocols should be 
proposed. Listing of the relevant qualifications and experience of 
the PI, associates, students, and technicians who will be involved 
with the test, although not specifically required by USDA-APHIS- 
BRS, may be useful for work requiring permit authorization. The 
proposed field-site assignment should be made by the appropriate 
field-site manager or equivalent party who oversees the field area 
where the test will be located so as to minimize exposure to other 
field tests, etc. (see Field-Site Selection, p.7).
A communication plan—drawn up by the PI in conjunction with 
the field-site manager (or equivalent) and approved by an authorized 
institutional official—should be included in the application to the IBC 
or designated approval body, and be in place for immediate use in the 
event of accidental release of bioengineered material. It is suggested 
that the IBC work with the PI and the institutional public relations or 
publicity office in the event that public response becomes necessary.
It is recommended that the proposal be reviewed by the IBC 
and suggestions incorporated in the submission to the regulatory 
agency(s). The institution should assign responsibility for seeking 
approvals to a single individual, usually the PI; the responsible 
person must adhere to the conditions placed on the permit by the 
regulatory agency(s).
It may be useful for the IBC to provide a generic application 
form to assure consideration of all relevant aspects and minimize 
preparation time for the PI; however, the application forms and 
information required by the regulatory agencies will be dictated by 
said agencies.
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Institutional Responsibility for Authorizations
Historically, the PI has been the party responsible for obtaining 
governmental authorizations. With increasing concerns over 
liability and quality control, some institutions have involved senior 
management in the process with, for example, the dean as cosignor. 
Each institution needs to establish its policy for who will be 
responsible for obtaining authorization and for implementation.
Approvals
All formal approvals (permits, notifications, consultations) 
required by external agencies must be obtained. Depending on 
the species and the generated product, small-plot field studies 
on experimental bioengineered plants require either notification 
of, or permits from, USDA-APHIS-BRS. An Experimental 
Use Permit (EUP) may also be needed from EPA for plant- 
incorporated protectants (PIPs) (e.g. Bt crops), usually when 
cumulative testing acreage exceeds 10 acres. For pharmaceutical- 
producing plants, early consultation with the FDA is suggested 
and adherence to their regulations/guidelines documented (see 
Appendix). Permitting procedures mandated by state and local 
municipalities must be followed.
The PI or other responsible institutional representative is 
required to determine the appropriate governmental agency(s) 
from which to obtain approvals. Current information on the 
regulatory processes of the federal agencies may be obtained 
from http://usbiotechreg.nbii.gov/index.asp and as follows:
• USDA-APHIS-BRS—http://www.aphis.usda.gov/ brs— 
biotech@aphis.usda.gov, 301-734-7324,
• EPA Office of Pesticide Programs/Biopesticides and Pollution 
Prevention Division—http://www.epa.gov/pesticides/biopesticides— 
Mike Mendelsohn, Senior Regulatory Specialist, mendelsohn. 
mike@epa.gov, 703-308-8715,
• FDA Center for Food Safety and Applied Nutrition (CFSAN)— 
http://www.cfsan.fda.gOv/~lrd/biotechm.html#reg— 
Kathleen Jones, Kathleen.Jones@cfsan.fda.gov, 301-436-1856.
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If a bioengineered plant is produced that, after consultation with 
the federal agencies, does not fall under the auspices of USDA- 
APHIS-BRS, FDA or EPA, it is recommended that the IBC review 
the proposal with institutional approval by a senior administrator 
identified by the institution.
Upon receipt of the required regulatory approvals, the responsible 
party will notify the other involved parties including the PI, the 
department chair, the agricultural experiment station director, the 
office of the vice-president for research and the appropriate field-site 
manager (or equivalents).
In addition to the above approvals, technology agreements for 
use of bioengineered seed or plant material provided by industry, 
purchased from industry, or secured from other parties for use in 
the field work may require formal approval from the source owner; 
formalizing such agreements should reduce risk to the PI and to 
the institution. The Pi’s responsibility may include adherence to 
additional third-party requirements for use of regulated materials.
Training
All personnel (PI, collaborating scientists, students, technicians, 
field workers, etc) including the field-site manager (or equivalent) 
who are, or may be, active in the field experimentation should 
complete a training course prior to their first field trial. It is strongly 
recommended that training be required for personnel conducting 
field trials on pharmaceutical-producing and industrial-product 
crops, so as to ensure understanding of all of the issues involved, 
and to ensure compliance with mandated operations. The training 
course will be developed (or adopted5), implemented, and monitored 
by the IBC and should include:
• explanation of what bioengineered plants are,
• necessity for confinement in field experimentation,
• possibilities for breach of confinement of field experiments,
• guidance provided by this document,
5Many institutional members have expressed interest in being provided a training docu­
ment. NABC is exploring availability of appropriate established training material; if and 
when available, this material will be provided as an appendix.
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• protocols required by the federal agencies for reporting accidental 
release of bioengineered material,
• examples of specific concerns associated with particular 
bioengineered materials,
• procedures for cleaning dedicated equipment,
• institutional assignment of specific oversight responsibilities to 
specific employees,
• consequences of non-compliance with federal and/or other 
regulations in terms of possible institutional and individual 
liability.
The IBC may require that the training course be taken prior to 
submission of the request for federal approval or prior to initiating 
the field trial.
The PI should affirm to the IBC in writing that all personnel 
involved in her/his field trial(s) with bioengineered plants have 
completed the training course. When significant changes occur 
in regulations—as judged by the IBC—the training material will 
be updated accordingly and all personnel involved in field trials 
should take the updated course or otherwise become familiar 
with the changes. Smaller institutions might use training facilities 
made available by larger institutions. It is recommended that a 
yearly refresher course be taken by all individuals who continue 
to participate in field trials with bioengineered crops, with written 
confirmation provided to the IBC.
Field-Site Selection6
Field sites for experiments with bioengineered crop plants should 
be chosen carefully. The PI is urged to consult with the field-site 
manager (or equivalent) as early as possible in the planning of the 
research to confirm availability of necessary equipment resources 
and to verify that federally mandated setback-distance requirements 
may be accommodated.
6Guidance for identification of a site suitable for field-testing a bioengineered plant. Set­
back distances, monitoring procedures, etc., will be as dictated by the permit issued by the 
USDA and/or EPA.
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Before testing bioengineered crop plants with pesticidal traits, it 
is crucial that Pis ensure that the PIP has a tolerance exemption that 
is legally applicable7, or that the experimental design ensures that 
no plant or genetic material from the trial enters the food supply. 
Without a tolerance or tolerance exemption in place for a PIP, foods 
containing PIP residues are considered to be adulterated and may 
not be moved in interstate commerce. Proper design of the test site 
is needed because of the potential for the PIP to inadvertently spread 
from test plants into other commercial, breeding or experimental 
crops and into the food supply. This can occur through cross­
pollination with surrounding crops, or the inadvertent mixing of 
seeds or other plant propagative material after harvest. To minimize 
the potential for such adulterants to enter the food supply, it is 
recommended that the PI or field site manager consult early with the 
EPA to ensure that appropriate physical and/or biological controls 
are in place to restrict the flow of genetic material, including pollen 
and seeds, from field tests.
The field-site manager (or equivalent person responsible for site 
assignment) will select the site after receiving input from the PI 
regarding characteristics of the bioengineered plant and objectives of 
the field test, taking into consideration the surrounding experimental 
and commercial plants and seed longevity, so as to ensure that no 
experimental transgenes enter commercial seed supplies. The field-site 
manager (or equivalent) and the PI should be aware of all regulations 
on follow-up procedures; any continuing use of the field site by the PI 
should be approved each year by the field-site manager.
On large experimental farms, when an experiment with 
bioengineered plants abuts an area supervised by a different field- 
site manager or is within the federally mandated setback distance 
of an area supervised by a different field-site manager, the field-site 
manager overseeing the bioengineered work needs to advise her/his
TAn example of a tolerance exemption that is not legally applicable for PIP is the 
Bacillus thuringiensis microbial pesticide exemption under 40 CFR 180.1011. 
This tolerance exemption is limited to pesticide products that contain B. thuringi- 
ensis microorganisms and does not apply to bioengineered crops with pesti­
cidal traits. Additionally, many PIP tolerances are crop- and protein-specific.
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counterpart accordingly in advance, preferably in writing. Similarly, 
when neighboring farms lie within the setback distance, the field- 
site manager should advise those farmers in advance, preferably 
in writing. It is suggested that a one-paragraph description of the 
experiment and its objectives in lay terms be provided by the PI. If 
a neighboring farmer requires additional information beyond that 
available to the field-site manager, it will be the responsibility of the 
PI to provide same.
NABC recommends that any site on which flooding has occurred 
not be used for trials with experimental bioengineered plants. Also, 
experiments with bioengineered plants on leased or farmers’ fields 
that do not involve the field-site manager (or equivalent) should involve 
institutional oversight, as described above and provide for monitoring, at 
least as required by the federal permit.
Record-Keeping and Communications
Records must encompass those required by the USDA-APHIS-BRS and/ 
or EPA permit. NABC recommends that the PI should keep all relevant 
records in secure hard-copy or electronic form, and suggests that each 
field and related operation be recorded, dated, and signed in timely fashion 
by the PI, or a person designated in writing by the PI. Also, a record 
of each current and all past trials with bioengineered plants should be 
prepared by the field-site manager (or equivalent) based on information 
provided by the PI, and kept on file for a suggested period of five years 
at the field-site office (or equivalent) applicable to the location of those 
trials and, as a backup, be regularly transferred to a central information 
repository (e.g. the office of the agricultural experiment station director 
and/or the institutional research office). A backup set of records—secure 
against loss by fire, theft, etc.—is advised.
Biological Materials: Storage
A dedicated facility, area, or container should be used for storage 
of all bioengineered materials (seeds, seedlings, and cuttings). All 
experimental bioengineered field-test materials covered by a federal 
permit should be kept in a locked facility. Each type of material— 
crop, transgene—will be physically separate from all others in a
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locked drawer, box, cabinet, etc., such as to eliminate any possibility 
of commingling or other confusion. Seed and other plant material 
should be labeled so as to be identifiable as bioengineered and 
distinguishable from all other bioengineered material.
Biological Materials: Post-Harvest Disposal
Unused bioengineered material approved by other than USDA- 
APHIS-BRS notification must be disposed of in accordance with 
the federal permit for the specific field experiment.
The bioengineered plant material must be devitalized before 
movement from the field site unless such movement and the destination 
facility are covered under the authorization. The method of disposal 
chosen will depend partly on the volume and type of material and 
whether leachate from devitalized material poses a hazard to the 
environment. Methods of disposal include tillage, herbicide treatment, 
landfill dumping and burial, autoclaving and incineration; the 
authorization will dictate the process and it is recommended that it be 
overseen by the institutional biosafety officer.
Equipment and Cleaning
Dedicated equipment is recommended by NABC for seed processing 
(te.g.cleaning, treatment), transportation, sowing, and harvesting of 
bioengineered plants for trials covered by a federal permit. Where 
dedicated equipment is not used, NABC recommends that a standard 
operating procedure for cleaning be in place with monitoring, to 
prevent carry-over of bioengineered material.
Dedicated equipment is not required for most USDA-APHIS- 
BRS field-test authorizations; however, dedicated equipment is 
required for trials with plants expressing pharmaceutical and 
industrial compounds.
All equipment used in a test with bioengineered material 
should be thoroughly cleaned after use in accordance with IBC- 
mandated protocols that are appropriate for foundation seed 
production or protocols for identity preservation, to prevent 
inadvertent movement.
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USDA-APHIS-BRS provides equipment-cleaning procedures 
for bio-engineered crops producing pharmaceutical and industrial 
compounds; before equipment is used on commercial material, 
USDA-APHIS-BRS may inspect it (http://www.aphis.usda.gov/brs/ 
fedregister/ BRS_20030310a.pdf).
Parti cular care i s needed when reassi gni ng a storage unit (container, 
area, or facility) so as to preclude carry-over ofbioengineered material. 
Cleaning methods will be provided by the IBC, and the institutional 
biosafety officer should oversee and approve the process.
Monitoring
NABC recommends that monitoring should include checks to 
ensure that approved protocols are being followed. In general, it 
is recommended for annual crops that the field site be monitored 
in the following growing season. USDA-APHIS-BRS uses a 
number of approaches to ensure compliance with the conditions 
associated with its field-test authorizations, including but not 
limited to site inspections and auditing of records. In trials of 
plants producing a pharmaceutical or industrial compound, 
USDA-APHIS-BRS monitors five times during the test year and 
twice in the following year.
NABC suggests that, in the case of a perennial crop, monitoring 
be extended, dependent on the species: for example, three years 
for bioengineered alfalfa. Also, the follow-up crop should be 
morphologically distinct from its bioengineered predecessor to 
enable detection of volunteers: for example, sorghum should not 
follow bioengineered corn.
Monitoring records should be treated as all others (see Record- 
Keeping and Communications, p. 9).
Testing
The PI may wish to develop and use appropriate tests (for the 
transgene or its product by PCR, ELISA, etc). Such tests would help 
to check for inadvertent presence ofbioengineered material.
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Reporting
A system for reporting should be established. Failure to follow 
protocol should be reported immediately to the IBC, to the institutional 
administration and other appropriate authorities, e.g. USDA-APHIS- 
BRS, EPA, FDA.
To address cases of failure to follow these guidelines, each FBC is 
encouraged to institute a plan of action approved by the authorized 
institutional administrator.
Review of Management of Bioengineered Field Tests
NABC will appoint an RMPs review committee selected 
from university, government, and industry professionals 
knowledgeable in field research, bioengineered plants, and the 
food/feed/fiber system. The committee will provide an on­
site review of any NABC-member institution that requests it, 
and will provide a written report on the institution’s field-test 
operations on bioengineered plants with recommendations for any 
needed improvements. The requesting institution will be responsible 
for the cost of the review.
All legal requirements for compliance with federal regulations 
are the responsibility of the institution at which the field-tests are 
conducted. An NABC review will provide only recommendations. 
NABC will assume no legal duty or responsibility for a member 
institution’s adoption or adherence to recommended management 
practices or for compliance with applicable laws and regulations in 
connection with any such review.
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Appendix
Federal Review
The federal government has a coordinated, risk-based system to ensure that new biotechnology products are safe for human 
and animal health and for the environment. Established as a formal 
policy in 1986, the Coordinated Framework for Regulation of 
Biotechnology describes the federal system for evaluating products 
developed through biotechnology (http://usbiotechreg.nbii. gov/ 
Coordi nated Framework l986_Federal Regi ster. htm 1).
The government agencies responsible for oversight of the 
products of agricultural biotechnology are USDA-APHIS-BRS, 
EPA, and FDA. Depending on its characteristics, a product may be 
subject to review by more than one of these agencies.
Further information is available at http://usbiotechreg.nbii.gov/ 
FAQAll.asp.
USDA-APHIS-BRS Approval Procedures8 
Approval by Notification
The notification procedure was first added to the regulation in 1993, 
at which time six plant species were potentially eligible as long as 
they met the other eligibility criteria described in the regulation for 
notification. In 1997, eligibility was broadened to include almost 
all plant species (the exception being those that are considered 
weed species in the locales where the tests are to be conducted). 
Eligibility criteria are included in the information provided at http:// 
www.aphis.usda.gov/ brs/7cfr340.html#340.
Regulated articles9 that meet the following six criteria [and 
performance standards defined in 340.3 Section (c)] are eligible for
8USDA-APHIS-BRS provides summary information on types of APHIS authorizations 
(permits and notifications) at http://www.aphis.usda.gov/brs/fieldtesting_importation. 
html. Additional explanations on the notification procedure, sample notification letters, 
and access to a User's Guide to notifications are available at http://www.aphis. usda.gov/ 
brs/notification.html.
9USDA-APHIS defines a “regulated article” as any organism which has been altered or 
produced through genetic engineering, if the donor organism, recipient organism, or vec­
tor or vector agent belongs to any genera or tarn designated in 340.2 (http://www.aphis. 
iisda.gov/brs/7cfr340. html#340.2) and meets the definition ofplant pest, or is an unclassi­
fied organism and/or an organism whose classification is unknown, or any product which
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introduction under the notification procedure. The eligibility criteria 
pertain to the plant in question, whereas the performance standards 
refer to the way the activities will be conducted.
• The regulated article is any plant species that is not listed as a 
noxious weed in regulations at 7 CFR part 360 under the Federal 
Noxious Weed Act (7 U.S.C. 2809), and, when being considered 
for release into the environment, the regulated article is not 
considered by the Administrator to be a weed in the area of 
release into the environment.
• The introduced genetic material is “stably integrated” in the plant 
genome, as defined in 340.1.
• The function of the introduced genetic material is known and 
its expression in the regulated article does not result in plant 
disease.
• The introduced genetic material does not:
- cause the production of an infectious entity, or
- encode substances that are known or likely to be toxic to 
nontarget organisms known or likely to feed or live on the 
plant species, or
- encode products intended for pharmaceutical use.
• To ensure the introduced genetic sequences do not pose a 
significant risk of the creation of any new plant virus, plant virus- 
derived sequences must be:
- noncoding regulatory sequences of known function, or
- sense or antisense genetic constructs derived from viral genes 
from plant viruses that are prevalent and endemic in the area 
where the introduction will occur and that infect plants of 
the same host species, and that do not encode a functional 
noncapsid gene product responsible for cell-to-cell movement 
of the virus.
• The plant has not been modified to contain the following genetic 
material from animal or human pathogens:
contains such an organism, or any other organism or product altered or produced through 
genetic engineering which the Administrator determines is a plant pest or has reason to be­
lieve is a plant pest. Excluded are recipient microorganisms which are not plant pests and 
which have resultedfrom the addition of genetic materialfrom a donor organism where the 
material is well characterized and contains only non-coding regulatory regions.
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- any nucleic acid sequence derived from an animal or human 
virus, or
- coding sequences whose products are known or likely causal 
agents of disease in animals or humans.
Approval by Permit
All other field trials with bioengineered plants require a permit as 
described under 7 CFR Part 340.4. This includes trials of plants 
bioengineered for industrial uses, e.g. chemicals, materials, and 
medicinals10. A precise definition of “industrial” is available at http:// 
www.aphis.usda.gov/ brs/fedregister/BRS_20050504a.pdf. Some 
traits that may be thought of as industrial may fall under notification, 
e.g. an over-expressed plant-derived product. It is recommended 
that first-time applicants consult USDA-APHIS-BRS to resolve any 
doubts.
EPA Experimental Use Permit
Before a pesticide can be marketed and used in the United States, 
the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 
requires that EPA evaluate the proposed pesticide to assure that its 
use will not pose unreasonable risks of harm to human health and 
the environment. The registration process involves an extensive 
review of health and safety information.
Plant-incorporated protectants are pesticidal substances produced 
by plants and the genetic material necessary for the plant to produce 
the substance. The genetic material and protein (e.g. Bt toxin)—but 
not the plant—are regulated by EPA.
Experimental use permits (EUPs) are issued for PIPs under 
Section 5 of FIFRA for the generation of information/data necessary
loin 1993 when the procedure was introduced, plants genetically engineered for industrial 
uses were eligible for notification. However, at that time, such plants were typically those 
in which nutritional components, such as oil content, had been altered and with which 
USDA-APHIS had significant regulatory experience. On August 6, 2003 (http://www. 
aphis.usda.gov/brs/fedregister/BRS_20030806a.pdf) USDA-APHIS announced an interim 
rule that introductions of plants genetically engineered to encode compounds for industrial 
use would generally be conducted under permit. In May 2005, USDA-APHIS announced 
adoption as a final rule of the interim rule of August 6,2003 (http://www.aphis.usda.gov/ 
brs/fedregister/BRS_20050504a.pdf).
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to register a pesticide under Section 3 of FIFRA. An EUP is required 
for testing an unregistered PIP or an unregistered use of a PIP on a 
cumulative total of over 10 acres. For pests that occur in different 
geographical situations, EUPs are required for testing PIPs on a 
cumulative total of over 10 acres per test. Further information is 
available at http://www.epa.gov/pesticides/biopesticides/pips/.
FDA Consultation
In the Federal Register of May 29,1992 (57 FR 22984), FDA publi shed 
its Statement of Policy: Foods Derived from New Plant Varieties 
(http://www.cfsan.fda.gov/~acrobat/fr920529.pdf), clarifying the 
agency’s interpretation of the application of the Federal Food, Drug, 
and Cosmetic Act when applied to food and feed derived from all 
new plant varieties, including those bioengineered.
The 1992 policy recommended that developers consult with 
FDA about bioengineered foods under development. In June 1996, 
FDA provided additional guidance to industry on procedures for 
these consultations (http://www.cfsan.fda.gov/%7Elrd/consulpr. 
html). These procedures describe a process in which a developer 
who intends to commercialize a bioengineered food meets with the 
agency to identify and discuss relevant safety, nutritional, or other 
regulatory issues regarding that food and then submits to FDA a 
summary of its scientific and regulatory assessment of the food; 
FDA evaluates the submission and responds to the developer by 
letter.
On November 24, 2004, FDA announced the availability of 
Guidance for Industry: Recommendations for the Early Food Safety 
Evaluation of New Non-Pesticidal Proteins Produced by New Plant 
Varieties Intended for Food Use (69 FR 68381; http://www.cfsan. 
fda.gov/~dms/bioprgui.html), to address the possibility that material 
from a new plant variety intended for food use might inadvertently 
enter the food supply before its sponsor has fully consulted with 
the FDA. This draft guidance discusses the early food safety- 
evaluation of new proteins in new plant varieties, particularly in new 
bioengineered varieties that are under development for possible use 
as food for humans or animals. The draft guidance also describes
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procedures for communicating with FDA about this evaluation. The 
issuance of the draft guidance was proposed in August 2002 in a 
Federal Register Notice (67 FR 50578) published by the Office of 
Science and Technology Policy as part of proposed federal actions 
to update field-test requirements and to establish early voluntary 
food safety evaluations for new proteins produced by bioengineered 
plants.
FDA guidance on biotechnology in general is available at http:// 
www.cfsan.fda.gov/ ~lrd/biotechm.html.
17
